Years in the un­mak­ing, CTI’s Pix­u­vri fails a piv­otal PhI­II com­bo study for lym­phoma — can it re­main on the mar­ket?

Seat­tle-based CTI Bio­Phar­ma’s $CTIC years-long saga de­vel­op­ing Pix­u­vri (pix­antrone) has run in­to an­oth­er stone wall. The com­pa­ny re­port­ed to­day that the drug, giv­en con­di­tion­al ap­proval …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER